Your browser doesn't support javascript.
loading
Glucocerebrosidase variant T369M is not a risk factor for Parkinson's disease in Sweden.
Ran, Caroline; Brodin, Lovisa; Gellhaar, Sandra; Westerlund, Marie; Fardell, Camilla; Nissbrandt, Hans; Söderkvist, Peter; Sydow, Olof; Markaki, Ioanna; Hertz, Ellen; Wirdefeldt, Karin; Svenningsson, Per.
Afiliación
  • Ran C; Department of Neuroscience, Karolinska Institutet, Solna, Sweden. Electronic address: caroline.ran@ki.se.
  • Brodin L; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Gellhaar S; Department of Neuroscience, Karolinska Institutet, Solna, Sweden.
  • Westerlund M; Department of Neuroscience, Karolinska Institutet, Solna, Sweden.
  • Fardell C; Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Nissbrandt H; Department of Pharmacology, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Söderkvist P; Faculty of Health Sciences, Division of Cell Biology, Department of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden.
  • Sydow O; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
  • Markaki I; Academic Specialist Center Torsplan, Stockholm, Sweden.
  • Hertz E; Academic Specialist Center Torsplan, Stockholm, Sweden.
  • Wirdefeldt K; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
  • Svenningsson P; Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden; Academic Specialist Center Torsplan, Stockholm, Sweden.
Neurosci Lett ; 784: 136767, 2022 07 27.
Article en En | MEDLINE | ID: mdl-35779693
ABSTRACT

INTRODUCTION:

Genetic variants in the Beta-glucocerebrosidase gene (GBA1) is a known risk factor for Parkinson's disease. The GBA1 mutations L444P, N370S and many other have been shown to associate with the disease in populations with diverse background. Some GBA1 polymorphisms have a less pronounced effect, and their pathogenicity has been debated. We have previously found associations with L444P, N370S and E326K and Parkinson's disease in Sweden.

METHOD:

In this study we used pyrosequencing to genotype the T369M variant in a large Swedish cohort consisting of 1,131 patients with idiopathic Parkinson's disease, and 1,594 control subjects to evaluate the possibility of this variant conferring an increased risk for Parkinson's disease.

RESULTS:

The minor allele frequency was 2.15% in patients and 1.76% in controls. Statistical analysis showed that there was no significant difference in allele frequency between patients and control subjects, p-value 0.37, Odds Ratio 1.23 with a 95% confidence interval of 0.82-1.83.

CONCLUSION:

Our results suggest that T369M is not a risk factor for Parkinson's disease in the Swedish population.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Glucosilceramidasa Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Neurosci Lett Año: 2022 Tipo del documento: Article

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Glucosilceramidasa Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans País/Región como asunto: Europa Idioma: En Revista: Neurosci Lett Año: 2022 Tipo del documento: Article